Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04350723
Other study ID # 2154
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 10, 2020
Est. completion date July 17, 2021

Study information

Verified date October 2021
Source St. Joseph's Healthcare Hamilton
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the COVI-PRONE Trial is to determine if early awake prone positioning in COVID-19 patients with hypoxemic respiratory failure; irrespective of the mode of oxygen delivery; reduces the need for invasive mechanical ventilation.


Recruitment information / eligibility

Status Completed
Enrollment 400
Est. completion date July 17, 2021
Est. primary completion date July 17, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults = 18 years of age. 2. Suspected or confirmed COVID-19. Defined as: a positive PCR for SARS CoV-2 or pending PCR results for patients that are suspected to have COVID-19. 3. Hypoxemia on room air (SPO2<90%), and oxygen requirement = 0.4 FiO2 (i.e. = 40% oxygen). 4. Bilateral or unilateral chest infiltrates on x-ray as interpreted by the treating team. 5. Admitted to the ICU or an acute care bed where hemodynamic and respiratory monitoring is feasible. Exclusion Criteria: 1. Immediate need for intubation as determined by the treating team. 2. Decreased level of consciousness (Glasgow Coma Scale score <10), or significant cognitive impairment hat may interfere with compliance (delirium, dementia) 3. Contraindication to proning including, but not limited to any of the following: Open chest or abdomen, abdominal surgery (i.e. laparotomy) within the 4 days, Unstable spine, facial, cervical, femur, or pelvic fractures. Limited neck mobility or inability to lie prone comfortably Skeletal deformities that interfere with proning. Complete bowel obstruction. Active upper gastrointestinal bleeding. Patient is unlikely/unable to prone, or to be compliant as indicated by the treating team. 4. Body mass index > 40 kg/m2 5. Pregnancy - third trimester. 6. Patient/substitute decision maker or caring physician's refusal to enroll in the study. 7. Patients with hemodynamic instability and moderate to high dose of vasopressors (norepinephrine dose = 0.15 mcg/kg/min) 8. Intubation is not within patient's goals of care 9. Patient received awake proning session for > 1 day prior to randomization 10. Previous intubation within the same hospital admission

Study Design


Intervention

Procedure:
Awake Proning
The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.

Locations

Country Name City State
Canada Univeristy of Calgary Calgary Alberta
Canada Hamilton General Hospital Hamilton Ontario
Canada Juravinski Hospital Hamilton Ontario
Canada St. Joseph's Healthcare Hamilton Hamilton Ontario
Canada CHU de Québec - Université Laval Quebec
Canada St. Catharine's General - St. Catharines Ontario
Canada Sinai Health System Toronto Ontario
Canada University Health Network - Toronto General Hospital Toronto Ontario
Kuwait Al-Amir Hospital Kuwait
Kuwait Jaber Al Ahmed hospital Kuwait
Saudi Arabia Prince Mohammed bin Abdulaziz Hospital Al Madinah
Saudi Arabia King Abdulaziz Hospital - NGHA AlAhsa
Saudi Arabia King Abdulaziz Medical City - Jeddah Jeddah
Saudi Arabia King Fahad Hospital of the University Khobar Eastern Province
Saudi Arabia King Abdulaziz Medical City Riyadh
Saudi Arabia King Faisal Specialist Hospital & Research Center Riyadh
United States University of Texas Health Sciences Centre Dallas Texas

Sponsors (4)

Lead Sponsor Collaborator
St. Joseph's Healthcare Hamilton Canadian Institutes of Health Research (CIHR), King Abdullah International Medical Research Center, McMaster University

Countries where clinical trial is conducted

United States,  Canada,  Kuwait,  Saudi Arabia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Endotracheal intubation Medical procedure in which a tube is placed into the windpipe (trachea) through the mouth. within 30 days of randomization
Secondary Mortality Death 60 days
Secondary Invasive mechanical ventilation free days Number of days not receiving mechanical ventilation censored at 30 Days
Secondary Non-invasive ventilation free days Number of days not receiving non-invasive mechanical ventilation censored 30 days
Secondary Days alive and outside ICU Number of days alive and outside the ICU 60 Days
Secondary Days alive and outside of hospital Number of days alive and outside of hospital 60 days
Secondary Complications from proning, Includes any of the following: accidental removal of intravenous access, hypotension, pressure injuries, or other. 30 days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure

External Links